Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
07
2019
accepted:
13
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
25
3
2020
Statut:
epublish
Résumé
Epithelial ovarian cancers are insidious pathologies that give a poor prognosis due to their late discovery and the increasing emergence of chemoresistance. Development of small pharmacological anticancer molecules remains a major challenge. Ribavirin, usually used in the treatment of hepatitis C virus infections and more recently few cancers, has been a suggestion. However, Ribavirin has many side-effects, suggesting that the synthesis of analogs might be more appropriate. We have investigated the effect of a Ribavirin analog, SRO-91, on cancer cell behavioral characteristics considered as some of the hallmarks of cancer. Two human ovarian adenocarcinoma cell lines (SKOV3 and IGROV1) and normal cells (mesothelial and fibroblasts) have been used to compare the effects of SRO-91 with those of Ribavirin on cell behavior underlying tumor cell dissemination. SRO-91, like Ribavirin, inhibits proliferation, migration, clonogenicity and spheroids formation of cancer cells. Unlike Ribavirin, SRO-91 is preferentially toxic to cancer compared with normal cells. An in vitro physiologically relevant model showed that SRO-91, like Ribavirin or cisplatin, inhibits cancer cell implantation onto peritoneal mesothelium. In conclusion, SRO-91 analog effects on tumor dissemination and its safety regarding non-cancerous (normal) cells are encouraging findings a promising drug for the treatment of ovarian cancer.
Identifiants
pubmed: 31825993
doi: 10.1371/journal.pone.0225860
pii: PONE-D-19-19287
pmc: PMC6905583
doi:
Substances chimiques
Ribavirin
49717AWG6K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0225860Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Lett. 2010 May 1;291(1):59-66
pubmed: 19880243
Cancer Cell. 2004 Jan;5(1):19-24
pubmed: 14749123
Clin Exp Metastasis. 2014 Aug;31(6):675-88
pubmed: 24946950
Cell Syst. 2017 Nov 22;5(5):445-459.e5
pubmed: 29102360
Curr Cancer Drug Targets. 2010 May;10(3):268-78
pubmed: 20370691
Cancer Res. 2015 Mar 15;75(6):1102-12
pubmed: 25608710
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Anticancer Res. 2009 Jun;29(6):1971-80
pubmed: 19528454
J Thorac Dis. 2018 Jul;10(7):3983-3991
pubmed: 30174840
Toxicol Appl Pharmacol. 1980 Jan;52(1):99-112
pubmed: 7361317
Haematologica. 2015 Jan;100(1):e7-9
pubmed: 25425688
Radiat Environ Biophys. 1981;19(3):205-14
pubmed: 7267987
Tumour Biol. 2008;29(4):231-44
pubmed: 18781095
Exp Cell Res. 2014 Jan 15;320(2):329-42
pubmed: 24291221
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18105-10
pubmed: 15601771
J Cell Biol. 2008 Nov 3;183(3):401-8
pubmed: 18955552
Blood. 2009 Jul 9;114(2):257-60
pubmed: 19433856
Biochem Biophys Res Commun. 2008 Oct 24;375(3):341-5
pubmed: 18706892
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
FASEB J. 2007 Jan;21(1):81-7
pubmed: 17135367
Clin Cancer Res. 2011 May 1;17(9):2874-84
pubmed: 21415224
Int J Cancer. 2005 Apr 20;114(4):531-43
pubmed: 15609323
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2286-2292
pubmed: 29959920
Endocr Rev. 2001 Apr;22(2):255-88
pubmed: 11294827
J Org Chem. 2009 Jun 5;74(11):4318-23
pubmed: 19438214
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Int J Cancer. 1999 Jan 18;80(2):285-94
pubmed: 9935212
Anticancer Res. 1996 Nov-Dec;16(6A):3307-12
pubmed: 9042305
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Mol Ther. 2004 Dec;10(6):1032-42
pubmed: 15564135
Cancer Res. 2004 Dec 1;64(23):8639-42
pubmed: 15574771
Tumour Biol. 2010 Apr;31(2):129-39
pubmed: 20358426
Oncol Res. 1999;11(5):243-7
pubmed: 10608619
Gynecol Oncol. 2007 May;105(2):373-84
pubmed: 17276501
Biophys J. 2008 Jun;94(12):4984-95
pubmed: 18326659
Beilstein J Org Chem. 2017 Apr 21;13:755-761
pubmed: 28503210
J Cell Physiol. 1989 Oct;141(1):65-73
pubmed: 2789227
Cell Biol Int. 2010 Apr 01;34(5):493-502
pubmed: 20121701
Leuk Lymphoma. 2010 Oct;51(10):1805-15
pubmed: 20629523